证券之星消息，8月1日医疗美容板块较上一交易日上涨0.06%，*ST美谷领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.12 | 2.30% | 11.73万 | 3619.67万 | | 688363 | 华熙生物 | 56'15 | 0.25% | 3.01万 | 1.57 Z | | 300896 | 爱美客 | 184.53 | -0.20% | 2.32万 | 4.31亿 | | 832982 | 锦波生物 | 322.91 | -3.46% | 1.04万 | 3.39亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1180.44万元，游资资金净流入977.47万元，散户 资金净流入202.97万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元 ...

Core Viewpoint - The Ministry of Industry and Information Technology of China has officially announced the first batch of "Biomanufacturing Iconic Products," which includes 36 products from various companies, marking a significant step in technological innovation and industrial upgrading in the biomanufacturing sector [1]. Summary by Relevant Sections Biomanufacturing Iconic Products - The list includes 36 companies such as Beijing Shulang Biotechnology, Micro Yuan Synthesis, and Qilu Pharmaceutical, showcasing the diversity and innovation within the biomanufacturing industry [1]. - The products range from biopharmaceuticals to food additives, indicating a broad application of biomanufacturing technologies across different sectors [1]. Notable Products - Ethanol Clostridium protein produced by Beijing Shulang is a feed protein supplement derived from microbial fermentation using industrial waste gases [4]. - Alotose, produced by Micro Yuan Synthesis, is a low-calorie sweetener that enhances production efficiency through microbial fermentation [4]. - Polyhydroxyalkanoate (PHA) from Beijing Microstructure is a biodegradable material that can replace plastics, reducing environmental pollution [4]. - CAR-T cell therapy product, Nakiolun, developed by Huyuan Biotechnology, shows significant advancements in cancer treatment [4]. - Various other products include natural extracts, amino acids, and vaccines, highlighting the innovative approaches in biomanufacturing [4][5][6][7]. Industry Significance - The announcement reflects the government's commitment to promoting the biomanufacturing industry, which is crucial for technological advancement and economic growth [1]. - The diversity of products indicates a growing trend towards sustainable and environmentally friendly manufacturing practices within the industry [1].

| 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 214.37万 | 7.42% | -53.63万 | -1.86% | -160.74万 | -5.57% | | 688363 华熙生物 | -420.73万 | -2.05% | 659.31万 | 3.22% | -238.58万 | -1.16% | | 300896 爱美客 | -7982.73万 | -13.22% | 2959.66万 | 4.90% | 5023.07万 | 8.32% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.05 | 1.33% | 9.42万 | 2888.14万 | | 832982 | 锦波生物 | 334.50 | -0.26% | 6835.71 | 2.28亿 | | 688363 | 华熙生物 | 51.82 | -2.04% | 3 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 随着年报披露收官，美容护肤行业上市公司财务总监薪酬面纱也被揭开。据数据统计，美容护肤行业上 市公司年薪为77万元，其中为财务总监支付的最高年度薪酬是珀莱雅，为财务总监王莉支付年薪293.3 万元；为CFO支付的最低年度薪酬是两面针，为原财务总监王为民支付年薪34.26万元。 美容护肤行业财务总监薪酬有近12家上市公司的财务薪酬超百万，分别为青松股份、锦波生物、登康口 腔、力合科创、华熙生物、中顺洁柔、稳健医疗、百亚股份、爱美客、华熙生物、贝泰妮、珀莱雅，这 些上市公司分别给财务总监支付年薪115万元、115.7万元、125.78万元、132.08万元、158.77万元、 168.41万元、201.5万元、204.78万元、233.5 ...

Group 1 - A total of 168 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more as of July 30 [1] - The stock with the longest consecutive net inflow days is Chunzhong Technology, which has seen net inflows for 16 trading days [1] - Other notable stocks with significant consecutive net inflow days include Longqi Technology, Daon Shares, Chengdi Xiangjiang, Huicheng Environmental Protection, Gaocai Shares, Juhe Materials, Wancheng Group, Huaxi Biological, and Xindian Software, with 14, 13, 13, 13, 11, 10, 10, 10, and 10 trading days of net inflows respectively [1]

证券之星消息，7月30日医疗美容板块较上一交易日上涨0.5%，爱美客领涨。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 209.44万 | 0.80% | -309.19万 | -1.19% | 99.75万 | 0.38% | | 000615 *ST美谷 | -221.92万 | -10.61% | -76.08万 | -3.64% | 298.00万 | 14.25% | | 300896 爱美客 | -1295.20万 | -1.73% | 3414.81万 | 4.56% | -2119.61万 | -2.83% | 从资金流向上来看，当日医疗美容板块主力资金净流出1307.69万元，游资资金净流入3029.54万元，散户 资金净流出1721.85万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104 ...

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688766 | 普冉股 | 7.79 | 5.03 | 64.60 | 68.94 | 6.72 | | | 份 | | | | | | | 300679 | 电连技 术 | 8.00 | 4.36 | 47.49 | 50.50 | 6.34 | | 300045 | 华力创 | 6.25 | 8.30 | 20.24 | 21.25 | 4.99 | | | 通 | | | | | | | 600238 | *ST椰岛 | 4.93 | 3.25 | 7.03 | 7.23 | 2.85 | | 300761 | 立华股 | 2.54 | 0.92 | 19.35 | 19.79 | 2.29 | | | 份 | | | | | | | 000703 | 恒逸石 化 | 2.13 | 0.30 | 6.09 | 6.22 | 2.09 | | ...

Group 1 - The medical beauty sector experienced a decline of 0.17% on July 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] - Major stocks in the medical beauty sector showed mixed performance, with Jinbo Biological up 1.82% and Ai Meike down 0.73% [1] Group 2 - The medical beauty sector saw a net outflow of 37.97 million yuan from main funds, while retail investors contributed a net inflow of 56.99 million yuan [1] - Specific stock performances included Huaxi Biological with a net outflow of 1.47 million yuan and *ST Meigu with a net inflow of 0.55 million yuan [2]

Core Viewpoint - The company, Huaxi Biological, has issued a statement denying false information circulated by certain online users, claiming it is fabricated and defamatory, and has reported the matter to law enforcement for legal action against the perpetrators [1][4][5]. Group 1: Incident Overview - Huaxi Biological discovered serious false information about the company posted on overseas websites, which they claim severely damages their reputation and includes political rumors [4]. - The individual responsible for the misinformation, Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. and was involved in a case of embezzlement amounting to 9 million yuan [4][5]. Group 2: Legal Actions and Company Response - Following the incident, Huaxi Xinyu reported the matter to law enforcement, which led to a criminal prosecution for Li under the charge of embezzlement [4]. - The company has taken a firm stance by filing a report with the police and intends to pursue legal action against those spreading false information, emphasizing the importance of maintaining a good environment in the capital market [5][6]. Group 3: Public Perception and Commentary - Commentators have noted that Huaxi's prompt response to the false claims is a wise decision, given Li's criminal background, which undermines the credibility of the information he disseminated [5]. - The company's actions are seen as a demonstration of respect for the law and a commitment to countering rumors, aiming to inform the public of the truth and prevent misinformation [6].

Group 1 - The medical beauty market in China is experiencing continuous growth, with the number of compliant specialized medical beauty institutions reaching 19,880 in the first half of 2024, an increase of 1,296 institutions or 7% from January 2024 [1][3] - The increase in compliant medical beauty institutions is driven by enhanced regulatory oversight and a growing consumer demand for legitimate medical beauty services [1][3] Group 2 - There is a significant shortage of compliant medical beauty doctors, with an estimated gap of around 20,000 qualified professionals, while the total number of medical beauty practitioners is approximately 1.02 million [4] - The annual growth rate of medical beauty practitioners is around 10%, but the supply of qualified professionals is only increasing at a rate of 5%-8%, highlighting a supply-demand imbalance [4] Group 3 - The distribution of medical beauty positions in China shows a clear imbalance, with only 10% of positions being medical technical roles, which require solid medical knowledge and qualifications [6] - Over 60% of positions are in marketing and operations, which are crucial for attracting customers and driving business growth, but this focus may compromise the quality of medical services [6] Group 4 - The educational requirements for core positions in the medical beauty industry are increasing, with a trend towards higher educational qualifications among professionals [9] - Large medical beauty companies are setting stricter educational standards, with some requiring a full-time bachelor's degree for medical technical roles [9] Group 5 - The distribution of medical beauty talent in China shows a pattern of concentration in eastern regions and high-tier cities, with first-tier cities holding over 50% of medical beauty positions [10] - New first-tier cities are competing for mid-level talent through differentiated strategies, while lower-tier cities struggle due to a lack of local training capabilities [10]